Radiopharmaceutical developer Navidea Biopharmaceuticals is highlighting a peer-reviewed study that assessed the performance of its fluorine-18-labeled amyloid imaging candidate.
The study, which was published in the current online edition of the Journal of Nuclear Medicine (JNM) and will appear in the June print edition, found that Navidea's NAV4694 imaging candidate displayed imaging characteristics that were nearly identical to those of the acknowledged gold standard amyloid imaging agent, carbon-11-labeled Pittsburgh Compound B (PiB), Navidea said.
The authors, who included Dr. Christopher Rowe, director of the department of nuclear medicine and Centre for PET at Austin Health in Melbourne, Australia, said the results show that NAV4694 may be useful in the early and differential diagnosis of Alzheimer's disease, Navidea said.
